Toggle light / dark theme

Researchers from the group of Hans Clevers (Hubrecht Institute) corrected mutations that cause cystic fibrosis in cultured human stem cells. In collaboration with the UMC Utrecht and Oncode Institute, they used a technique called prime editing to replace the ‘faulty’ piece of DNA with a healthy piece. The study, published in Life Science Alliance on August 9 shows that prime editing is safer than the conventional CRISPR/Cas9 technique. “We have for the first time demonstrated that this technique really works and can be safely applied in human stem cells to correct cystic fibrosis.”

Cystic fibrosis (CF) is one of the most prevalent genetic diseases worldwide and has grave consequences for the patient. The mucus in the lungs, throat and intestines is sticky and thick, which causes blockages in organs. Although treatments are available to dilute the mucus and prevent inflammations, CF is not yet curable. However, a new study from the group of Hans Clevers (Hubrecht Institute) in collaboration with the UMC Utrecht and Oncode Institute offers new hope.

Correcting CF mutations

The researchers succeeded in correcting the that cause CF in human intestinal organoids. These organoids, also called mini-organs, are tiny 3D structures that mimic the intestinal function of patients with CF. They were previously developed by the same research group from stem cells of patients with CF and stored in a biobank in Utrecht. For the study, published in Life Science Alliance, a technique named prime editing was used to replace the piece of mutated DNA that causes CF with a healthy piece of DNA in these organoids.

Since DNMT3A increases DNA methylation, the researchers used a natural product that donates methyl groups S-adenosylmethionine (SAMe) and to activate the retinoic acid receptor they treated the animals with vitamin A. They found that combined treatment with the methyl donor SAM and retinoic acid reversed PTSD-like behaviors.


Summary: Combining two natural products that modulate the epigenome, researchers believe they have identified a feasible approach to reversing symptoms of PTSD in animal models that could be effective in humans.

Source: Bar Ilan University

Exposure to a traumatic experience can lead to post-traumatic stress disorder (PTSD), an incapacitating disorder in susceptible persons with no reliable therapy. Particularly puzzling is understanding how transient exposure to trauma creates persistent long-term suffering from PTSD and why some people are susceptible to PTSD while others that were exposed to the same trauma remain resilient.

Epigenetic modifications are chemical marks on genes that program their activity. These marks are written into DNA during fetal development to correctly program how our genes function in different organs. However, research in the last two decades has suggested that these marks could also be modulated by experiences and exposures at different point of time in life.

ADS Codex translates binary data into nucleotides that can be sequenced in molecules as files for later retrieval, bringing potential cost savings and compact ‘cold storage.’

In support of a major collaborative project to store massive amounts of data in DNA

DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Through a process known as RNA interference (RNAi), scientists have been able to modify the genetic make-up of the daddy long-legs arachnid so that its distinctive spindly limbs become twice as short.

This process – which uses a gene’s own DNA sequence and small fragments of RNA to turn the gene off – was applied to the Phalangium opilio species, one of the most common species of daddy long-legs in the world.

The result is effectively a daddy short-legs instead of a daddy long-legs. The team behind the work is hoping that the experiments can teach us more about how these elongated limbs evolved in the first place.

Gene-editing technique CRISPR may deliver new treatments for genetic diseases—and it’s already being tested on patients.


17:22 minutes.

In one of the first clinical applications of the technique, last month researchers reported in the New England Journal of Medicine that CRISPR had stopped a genetic disease called amyloidosis, which occurs when an abnormal protein accumulates in your organs. They’re not the only group moving toward using CRISPR on humans; recently, the FDA approved a human clinical trial that will use the technique to edit genes responsible for sickle cell disease.

A new tool helps researchers explore the types of cells that make up brain organoids — clusters of cells that can mimic the basic structure, function and development of different parts of the brain.

The software, detailed in Cell Stem Cell, maps information about when and where genes are expressed in brain organoids onto a reference atlas of the developing mouse brain. Scientists can use the resulting overlay to develop organoids that better recapitulate the developing brain, the team says, or to uncover the effects of gene mutations and other experimental perturbations.

Brain organoids derived from the cells of people with conditions such as autism have proved useful in capturing neuronal abnormalities. But the findings are muddied by methodological differences in how researchers develop these lab-grown blobs. Advanced techniques to profile gene expression in single cells have made it easier to identify the cell types in any given organoid. But it’s remained difficult to map those cell types onto different brain regions.

Three pioneering technologies have forever altered how researchers do their work and promise to revolutionize medicine, from correcting genetic disorders to treating degenerative brain diseases.

Some mutations that disable SCN2A, one of the genes most strongly linked to autism, can unexpectedly make neurons hyperexcitable, a study in mice shows. The findings may help explain why a sizeable proportion of autistic children with mutations in SCN2A experience epileptic seizures.


Deleterious mutations in an autism-associated gene can make neurons hyperexcitable, raising the risk of epileptic seizures.

A couple people from TRIM are in TRIM-X to see how it works a second time.


In this video Dr. Fahy discusses what we can do to make the most of our thymus without the growth hormone treatment, what the timing makes sense for rejuvenation of the thymus and whether the thymus is tied to the other hallmarks of aging.

Dr. Greg Fahy is a world renowned cryobiologist and is also the chief science officer, and co-founder, of Intervene Immune, a company which pioneers treatments for thymus regeneration and age-related immune system decline. Dr. Fahy Designed and led the pilot TRIIM trial which first time showing both thymus rejuvenation and reversal of human epigenetic age. He is now running the follow up phase II trial TRIIM-X with the aim of confirming and extending the results.

************************************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.

Audio Copyright Disclaimer:
Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected].

*****************************************************************
If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan

Driver Clocks And Longevity — Dissecting True Functional “Drivers” Of Aging Phenotypes — Dr. Daniel Ives Ph.D., Founder and CEO — Shift Bioscience Ltd.


Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning ‘driver’ clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based.

Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute, pursuing damage-removal strategies for mitochondrial DNA mutations.

In 2016 Dr. Ives left the Crick Institute and founded Shift Bioscience to commercialize mitochondrial targeted drugs for age linked diseases, incorporating novel ageing biomarkers technologies, CRISPR screens, and other tools to dissect true functional ‘drivers’ of ageing phenotypes.